Supplemental Data:

The *CLB2* DNA binding activity does not involve Mcm1 protein. A. Addition of anti-HA antibody against the triple HA tagged Mcm1 protein causes a supershift of the yeast heparin agarose-purified protein-*CLN3* DNA complexes resolved by EMSA but has no effect on mobility of the yeast heparin agarose-purified protein-*CLB2-L2* DNA complexes. B. Mobility of EMSA *CLB2-L2* (-933 to –622)-protein complexes is not affected by changes in the size of Mcm1p. Complexes with *CLB2-L2*, produced using crude extracts from strains that produce either full length or truncated Mcm1 proteins, is similar. Crude extracts were made from EJG573, *MCM1 (1-286)-(HA)$_3$ Δpep::URA3*, lanes 1 and 2; YT1091 *MCM1 (1-286)-(HA)$_3$* lanes 3 and 4; MHK7.2.4 *MCM1(1-98)-(HA)$_3$*, lanes 5 and 6. The triple HA epitope increases the size of each Mcm1 protein by 54 amino acids.



Figure 2. DNA binding to full length *CLB2-L2* (-933 to –622), assessed by EMSA, is competed by an oligonucleotide bearing only 26 base pairs of *CLB2* (corresponding to the protected sequence –795 to -770). The data in Figure 3C was evaluated by Scatchard analysis to determine the apparent K_D using the oligonucleotide as competitor for binding to the entire *CLB2-L2*. The apparent K_D is 3×10^{-10} M.